Cargando…

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

BACKGROUND: Limited utility data on patients suffering from overactive bladder (OAB) are available in the literature. The objectives of this study were to estimate utility values in patients with OAB using the generic EQ-5D questionnaire and the OAB-5D disease specific questionnaire, to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desroziers, Katia, Aballéa, Samuel, Maman, Khaled, Nazir, Jameel, Odeyemi, Isaac, Hakimi, Zalmai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842710/ https://www.ncbi.nlm.nih.gov/pubmed/24246044 http://dx.doi.org/10.1186/1477-7525-11-200

Ejemplares similares

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France
por: Wojciechowski, Piotr, et al.
Publicado: (2023)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB)
por: Khizer, Zara, et al.
Publicado: (2023)

Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder
por: Notte, Sherilyn M, et al.
Publicado: (2012)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review
por: Khizer, Zara, et al.
Publicado: (2021)

The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population
por: Lai, H. Henry, et al.
Publicado: (2016)

Do we need more patient‐friendly treatment options for overactive bladder (OAB)?
por: Gerig, Nel, et al.
Publicado: (2021)

AB316. SPR-43 Comparison of bladder volumes between 2D and 3D ultrasound calculations and urodynamic measurements in women with overactive bladder (OAB)
por: Bernardo, Rachel J., et al.
Publicado: (2016)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population
por: Oh, Seung-June, et al.
Publicado: (2012)

Selective bladder denervation for overactive bladder (OAB) syndrome: From concept to healing outcomes using the ovine model
por: Fugett, James, et al.
Publicado: (2018)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)

Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management
por: Turell, Wendy, et al.
Publicado: (2020)

Do Older Adults with Overactive Bladder Demonstrate Impaired Executive Function Compared to Their Peers Without OAB?
por: Gibson, William, et al.
Publicado: (2020)

Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis
por: Koszorú, Kamilla, et al.
Publicado: (2022)

Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients
por: Golicki, Dominik, et al.
Publicado: (2014)

Population norms for the EQ-5D-3L and EQ-5D-5L in Romania
por: Olariu, Elena, et al.
Publicado: (2023)

EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
por: Hawe, Emma, et al.
Publicado: (2016)

Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments
por: Wolfs, Claire AG, et al.
Publicado: (2007)

Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
por: Wille, Nora, et al.
Publicado: (2010)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
por: Herdman, M., et al.
Publicado: (2011)

Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults
por: Ferreira, Lara N., et al.
Publicado: (2016)

Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
por: Mulhern, Brendan, et al.
Publicado: (2018)

Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values
por: Selivanova, Anna, et al.
Publicado: (2018)

Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population
por: You, Ruxu, et al.
Publicado: (2020)

Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder
por: Jaggi, Ashley, et al.
Publicado: (2021)

Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients
por: Pattanaphesaj, Juntana, et al.
Publicado: (2015)

Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
por: Mulhern, Brendan, et al.
Publicado: (2018)

EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories
por: Kreimeier, Simone, et al.
Publicado: (2019)

The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa
por: Bató, Alex, et al.
Publicado: (2021)

Psychometric properties of the EQ-5D-5L compared with EQ-5D-3L in cancer patients in Iran
por: Moradi, Nasrin, et al.
Publicado: (2022)

Validity of EQ-5D-5L in stroke
por: Golicki, Dominik, et al.
Publicado: (2014)

Valuation of the EQ-5D-5L in Taiwan
por: Lin, Hsiang-Wen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h3sej41liadmdptlbkd7vdpma0